PMID- 23923083
OWN - NLM
STAT- MEDLINE
DCOM- 20140321
LR  - 20211021
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 6
IP  - 8
DP  - 2013
TI  - Primary anaplastic large cell lymphoma in the dura of the brain: case report and 
      prediction of a favorable prognosis.
PG  - 1643-51
AB  - Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma composed of 
      CD30-positive lymphoid cells. ALCL arising in the dura matter of the brain is 
      even more infrequent, in which only one case has been reported worldwide so far. 
      We report a case of a 30-year-old immunocompetent male with a dura-based mass, 
      radiographically consistent with meningioma. However, the excised mass via a left 
      parieto-occipital craniotomy was composed of large, pleomorphic lymphoid cells to 
      be immunopositive for CD3, CD30, anaplastic lymphoma kinase protein-1 (ALK-1) and 
      epithelial membrane antigen (EMA), and immunonegative for CD20, CD15 and CD68. 
      Multiple ALK gene fusion signals in the ALK locus were detected by fluorescence 
      in situ hybridization (FISH) analysis. The patient was treated with CHOP 
      chemotherapy and intrathecal methotrexate along with brain radiation therapy, 
      which resulted in a complete remission. In an analysis of 25 previously reported 
      primary CNS ALCLs, ALK-1 positivity was shown to be prevalent in younger age, as 
      ALCL occurs outside the brain. Patient less than 23 years, ALK-1 positivity and 
      unifocal tumor may be associated with a better prognosis. However, sex, dural or 
      leptomeningeal involvement, immune status, and tumor necrosis do not appear to 
      have any influence on survival.
FAU - Kim, Min-Kyung
AU  - Kim MK
AD  - Department of Pathology, School of Medicine, Catholic University of Daegu, Daegu, 
      Republic of Korea.
FAU - Cho, Chang-Ho
AU  - Cho CH
FAU - Sung, Woo-Jung
AU  - Sung WJ
FAU - Ryoo, Hun-Mo
AU  - Ryoo HM
FAU - Lee, Ho-Jun
AU  - Lee HJ
FAU - Youn, Sung-Won
AU  - Youn SW
FAU - Park, Kwan-Kyu
AU  - Park KK
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20130715
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Adult
MH  - Anaplastic Lymphoma Kinase
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Combined Modality Therapy
MH  - Cranial Irradiation
MH  - Cyclophosphamide
MH  - Doxorubicin
MH  - Dura Mater/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large-Cell, Anaplastic/genetics/*pathology/*therapy
MH  - Male
MH  - Meningeal Neoplasms/genetics/*pathology/*therapy
MH  - Oncogene Proteins, Fusion/genetics
MH  - Prednisone
MH  - Prognosis
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Vincristine
PMC - PMC3726981
OTO - NOTNLM
OT  - ALK-positive
OT  - Anaplastic large cell lymphoma
OT  - dura
OT  - primary tumor
OT  - prognosis
EDAT- 2013/08/08 06:00
MHDA- 2014/03/22 06:00
PMCR- 2013/07/15
CRDT- 2013/08/08 06:00
PHST- 2013/06/18 00:00 [received]
PHST- 2013/07/10 00:00 [accepted]
PHST- 2013/08/08 06:00 [entrez]
PHST- 2013/08/08 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
PHST- 2013/07/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 Jul 15;6(8):1643-51. Print 2013.